The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Ignyta; Merck; MSD; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Ignyta; Merck; MSD; Novartis; Pfizer; Roche; Takeda
Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).
 
Keunchil Park
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Daiichi Sankyo; Hanmi; Lilly; LOXO; Merck KGaA; MSD; Novartis; Ono Pharmaceutical; Roche
Speakers' Bureau - AZD; Boehringer Ingelheim
Research Funding - AstraZeneca; MSD Oncology
 
Thomas John
No Relationships to Disclose
 
Sang-We Kim
No Relationships to Disclose
 
Jong Seok Lee
No Relationships to Disclose
 
Catherine A. Shu
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim
Research Funding - Celgene (Inst); Genentech/Roche (Inst); Janssen (Inst); MedImmune (Inst)
Travel, Accommodations, Expenses - Genentech/Roche
 
Dong-Wan Kim
Research Funding - Alpha Biopharma (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Hanmi (Inst); Janssen (Inst); Merus (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst); TP Therapeutics (Inst); Xcovery (Inst); Yuhan (Inst)
Travel, Accommodations, Expenses - Amgen; Daiichi Sankyo
 
Santiago Viteri Ramirez
Consulting or Advisory Role - Bristol-Myers Squibb; Roche
Speakers' Bureau - Bristol-Myers Squibb; Roche
Research Funding - Boehringer Ingelheim (Inst); Exelixis (Inst); iOMEDICO (Inst); Merck Serono (Inst); Novocure (Inst); ose pharma (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Merck Serono; ose pharma (Inst); Roche
 
Alexander I. Spira
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; CytomX Therapeutics; Merck; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); incyte; Novartis
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); Arch Therapeutics (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novartis (Inst); Plexxikon (Inst); Roche (Inst); Takeda (Inst); Trovagene (Inst)
 
Joshua K. Sabari
Consulting or Advisory Role - AstraZeneca
 
Ji-Youn Han
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD Oncology; Novartis; Pfizer; Takeda
Research Funding - Ono Pharmaceutical; Pfizer; Roche; Takeda
 
Jose Manuel Trigo
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Takeda
Speakers' Bureau - AstraZeneca; Bayer; Eisai; Merck Sharp & Dohme
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme
 
Chee Khoon Lee
Honoraria - AstraZeneca; Boehringer Ingelheim; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Novartis; Pfizer
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim
 
Ki Hyeong Lee
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD
 
Nicolas Girard
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; MSD; Novartis; Pfizer; Pharmamar; Roche; Takeda
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD Oncology; Roche
 
Patricia A Lorenzini
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
 
John Xie
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
 
Amy Roshak
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
 
Meena Thayu
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
 
Roland Elmar Knoblauch
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson; Johnson & Johnson (I)
Travel, Accommodations, Expenses - Johnson & Johnson
 
Byoung Chul Cho
Stock and Other Ownership Interests - Bridgebio; Gencurix; Theravance
Honoraria - AstraZeneca; Bayer; Champions Oncology; Dizal Pharma; Dong-A ST; Janssen; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda; Yuhan
Speakers' Bureau - Novartis
Research Funding - AstraZeneca; Bayer; Champions Oncology; Dizal Pharma; Dong-A ST; Janssen; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology